Xencor, Inc. (XNCR) Earnings
Xencor, Inc. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.84. XNCR has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +14.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.65 | $-1.71 | -163.1% | $5M | -83.8% |
| Feb 25, 2026 | $-0.66 | $-0.09 | +86.4% | $28M | -5.8% |
| Nov 5, 2025 | $-0.72 | $-0.08 | +88.9% | $21M | -29.9% |
| Aug 6, 2025 | $-0.78 | $-0.41 | +47.4% | $44M | +78.9% |
| May 7, 2025 | $-0.63 | $-0.66 | -4.8% | $33M | +45.5% |
| Feb 27, 2025 | $-0.81 | $-0.62 | +23.5% | $70M | +313.3% |
| May 9, 2024 | $-0.76 | $-1.11 | -46.1% | $13M | -48.8% |
| Feb 27, 2024 | $0.36 | $-0.31 | -186.1% | $45M | -39.5% |
| Aug 3, 2023 | $-0.91 | $-0.37 | +59.3% | $46M | +57.0% |
| Feb 23, 2023 | $-0.83 | $-0.20 | +75.9% | $22M | +7.7% |
| Aug 3, 2022 | $-0.45 | $-0.57 | -26.7% | $30M | -11.3% |
| May 5, 2022 | $-0.61 | $0.39 | +163.9% | $85M | +227.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2023 · February 28, 2024
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Focused pipeline and discovery work on T-cell engagers for solid tumors, with updates on vudalimab in prostate cancer (monotherapy cohort with encouraging responses) and initiation of a front-line non-small cell lung cancer study. • Partnerships with Amgen, including promising data from Xaluritamig in late-line prostate cancer. • Progress on XmAb bispecifics: XmAb819 (ENPP3 in renal cell carcinoma) advancing in dose escalation; XmAb808 (CD28 targeting) in Phase 1; XmAb541 (CLDN6) to start Phase 1 in H1 2024. • Strengthened balance sheet with partial monetization of royalties, ending 2023 with $697 million and runway into 2027. • Wrapping up Phase 1 work for XmAbs 564 and 662, focusing resources on T-cell engagers.
Guidance
• 2024 priorities focus on solid tumor bispecifics pipeline. • Intend to select next IND candidate later in 2024.
Segment performance
No specific segment performance data on absolute terms and revenue contribution provided in the transcript.
Risks & headwinds
Forward-looking statements subject to known and unknown risks, uncertainties, and factors from the company's most recently filed annual report on Form 10-K, but no specific operational failures detailed in the Q&A.
Analyst Q&A
Q: Comment on when initial clinical data from ENPP3 study might be seen.
A: Bassil stated they are working on characterizing the dose and will disclose when close to having data to share.
Q: Bar for go-forward decisions on vudalimab mono and combo.
A: Dane discussed comparing with peer studies, with RECIST response and deep PSA response as key factors.
Q: Safety of vudalimab, including autoimmune hepatitis and pause of XmAb564.
A: Bassil said XmAb564 pause was strategy-driven due to focus on T-cell engagers; Nancy discussed the single hepatitis case and monitoring protocols.
Q: Monotherapy data molecular subtype, PSA comparison.
A: Bassil said the monotherapy study isn't subdivided by molecular subtype; Dane explained PSA differences due to measurable disease vs. bone-only patients.
Q: Safety vs IPI/NIVO, dose going forward, enrollment numbers, bone responses.
A: Nancy said vudalimab safety is similar to other checkpoint inhibitors; dose is Q3 week flat; aiming for ~30 patients in monotherapy and combo cohorts.
Q: Background of confirmed responders, low-hanging fruit in mCRPC.
A: Nancy discussed heavily pretreated patients; Dane talked about comparators and future combination possibilities.
Q: Benchmark for vudalimab monotherapy, quality-of-life data.
A: Dane said waiting for cohort totals and using peer studies as comparators, with future plans to evaluate quality-of-life once cohorts are larger